Kronenberger et al. [61] detected the systemic levels of IL-22 in 120 LC patients and 40 healthy donors and found that IL-22 was more detectable in LC patients compared with healthy donors (74.1% vs. 10%), and the patients with elevated IL-22 levels had a reduced survival time (321 days vs. 526 days). The gene discussed is IL22; the disease is laryngotracheoesophageal cleft.